Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.
Epistemonikos ID: 54171b41319ca7799fb9b0c695a43af6720398b8
First added on: Oct 17, 2026